Monoclonal Antibodies Targeting Surface-Exposed Epitopes of Candida albicans Cell Wall Proteins Confer In Vivo Protection in an Infection Model

Monoclonal antibody (mAb)-based immunotherapies targeting systemic and deep-seated fungal infections are still in their early stages of development, with no licensed antifungal mAbs currently being available for patients at risk. The cell wall glycoproteins of Candida albicans are of particular inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Palliyil, Soumya, Mawer, Mark, Alawfi, Sami A., Fogg, Lily, Tan, Tyng H., De Cesare, Giuseppe Buda, Walker, Louise A., MacCallum, Donna M., Porter, Andrew J., Munro, Carol A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017365/
https://www.ncbi.nlm.nih.gov/pubmed/35285676
http://dx.doi.org/10.1128/aac.01957-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017365/
https://www.ncbi.nlm.nih.gov/pubmed/35285676
http://dx.doi.org/10.1128/aac.01957-21

Ejemplares similares